Ramachandran Murali

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6407490/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis. Nature Communications, 2022, 13, 669.	12.8	19
2	Asporin, an extracellular matrix protein, is a beneficial regulator of cardiac remodeling. Matrix Biology, 2022, 110, 40-59.	3.6	16
3	Co-Variation of Serum Osteoprotegerin and Pigment-Epithelial Derived Factor as Biomarker of Pancreatic Cancer Austin Journal of Gastroenterology, 2022, 9, .	0.0	0
4	Elevated Asparagine Biosynthesis Drives Brain Tumor Stem Cell Metabolic Plasticity and Resistance to Oxidative Stress. Molecular Cancer Research, 2021, 19, 1375-1388.	3.4	6
5	Should All Memory B Cells Recruited to the Germinal Center Be Antigen Specific?. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2021, 40, 50-51.	1.6	0
6	The Effects of Receptor Activator of NF-κB Ligand-Binding Peptides on Bone Resorption and Bone Formation. Frontiers in Cell and Developmental Biology, 2021, 9, 648084.	3.7	4
7	Disabling the Nuclear Translocalization of RelA/NF-κB by a Small Molecule Inhibits Triple-Negative Breast Cancer Growth. Breast Cancer: Targets and Therapy, 2021, Volume 13, 419-430.	1.8	4
8	Rational Design of Constrained Peptides as Protein Interface Inhibitors. Antibodies, 2021, 10, 32.	2.5	0
9	Challenges in Detection of Serum Oncoprotein: Relevance to Breast Cancer Diagnostics. Breast Cancer: Targets and Therapy, 2021, Volume 13, 575-593.	1.8	1
10	Dual targeting of GSK3B and HDACs reduces tumor growth and improves survival in an ovarian cancer mouse model. Gynecologic Oncology, 2020, 159, 277-284.	1.4	12
11	iPSC modeling of young-onset Parkinson's disease reveals a molecular signature of disease and novel therapeutic candidates. Nature Medicine, 2020, 26, 289-299.	30.7	102
12	c-Rel is a myeloid checkpoint for cancer immunotherapy. Nature Cancer, 2020, 1, 507-517.	13.2	63
13	Perspective on Crystallographic Studies of Antibody Structures. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2020, 39, 195-198.	1.6	1
14	EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2019, 18, 1341-1354.	4.1	41
15	The induction of RANKL molecule clustering could stimulate early osteoblast differentiation. Biochemical and Biophysical Research Communications, 2019, 509, 435-440.	2.1	16
16	ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. Nature Medicine, 2018, 24, 1887-1898.	30.7	113
17	An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice. Gastroenterology, 2018, 155, 1985-1998.e5.	1.3	61
18	Structure of a Thyrotropin Receptor Monoclonal Antibody Variable Region Provides Insight into Potential Mechanisms for its Inverse Agonist Activity. Thyroid, 2018, 28, 933-940.	4.5	2

#	Article	IF	CITATIONS
19	Nuclear receptor/Wnt beta-catenin interactions are regulated via differential CBP/p300 coactivator usage. PLoS ONE, 2018, 13, e0200714.	2.5	16
20	Baicalein Targets GTPaseâ€Mediated Autophagy to Eliminate Liver Tumor–Initiating Stem Cell–Like Cells Resistant to mTORC1 Inhibition. Hepatology, 2018, 68, 1726-1740.	7.3	55
21	Stearoyl-CoA Desaturase Promotes Liver Fibrosis and Tumor Development in Mice via a Wnt Positive-Signaling Loop by Stabilization of Low-Density Lipoprotein-Receptor-Related Proteins 5 and 6. Gastroenterology, 2017, 152, 1477-1491.	1.3	133
22	Direct Antimicrobial Activity of IFN-β. Journal of Immunology, 2017, 198, 4036-4045.	0.8	48
23	The intra-articular injection of RANKL-binding peptides inhibits cartilage degeneration in a murine model of osteoarthritis. Journal of Pharmacological Sciences, 2017, 134, 124-130.	2.5	10
24	HER2-positive breast cancer targeting and treatment by a peptide-conjugated mini nanodrug. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 631-639.	3.3	36
25	Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer. PLoS ONE, 2017, 12, e0171356.	2.5	33
26	Anti-Her2/Neu Peptide Mimetic. , 2017, , 1-4.		0
27	Delivery of RANKL-Binding Peptide OP3-4 Promotes BMP-2–Induced Maxillary Bone Regeneration. Journal of Dental Research, 2016, 95, 665-672.	5.2	19
28	Trastuzumab-Resistant Luminal B Breast Cancer Cells Show Basal-Like Cell Growth Features Through NF-κB-Activation. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2016, 35, 1-11.	1.6	10
29	Peptide-induced de novo bone formation after tooth extraction prevents alveolar bone loss in a murine tooth extraction model. European Journal of Pharmacology, 2016, 782, 89-97.	3.5	13
30	Peptide drugs accelerate BMPâ€2â€induced calvarial bone regeneration and stimulate osteoblast differentiation through mTORC1 signaling. BioEssays, 2016, 38, 717-725.	2.5	25
31	The Potential Role of Solvation in Antibody Recognition of the Lewis Y Antigen. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2015, 34, 295-302.	1.6	4
32	Group B Streptococcus Evades Host Immunity by Degrading Hyaluronan. Cell Host and Microbe, 2015, 18, 694-704.	11.0	66
33	The inhibitory effects of a RANKL-binding peptide on articular and periarticular bone loss in a murine model of collagen-induced arthritis: a bone histomorphometric study. Arthritis Research and Therapy, 2015, 17, 251.	3.5	36
34	Crystal Structure of a TSH Receptor Monoclonal Antibody: Insight Into Graves' Disease Pathogenesis. Molecular Endocrinology, 2015, 29, 99-107.	3.7	19
35	Alternatively activated macrophages promote pancreatic fibrosis in chronic pancreatitis. Nature Communications, 2015, 6, 7158.	12.8	264
36	Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer. Clinical Breast Cancer, 2015, 15, 448-457.e2.	2.4	11

#	Article	IF	CITATIONS
37	Anti-Her2/Neu Peptide Mimetic. , 2015, , 1-4.		Ο
38	Anti-Her2/Neu Peptide Mimetic. , 2015, , 279-283.		0
39	Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunities. Frontiers in Physiology, 2014, 5, 478.	2.8	40
40	Carbohydrate-Mimetic Peptides for Pan Anti-Tumor Responses. Frontiers in Immunology, 2014, 5, 308.	4.8	23
41	Human immunodeficiency virus type 1 Vpr polymorphisms associated with progressor and nonprogressor individuals alter Vpr-associated functions. Journal of General Virology, 2014, 95, 700-711.	2.9	17
42	Defining the Recognition Elements of Lewis Y-Reactive Antibodies. PLoS ONE, 2014, 9, e104208.	2.5	6
43	Mutations in K-Ras linked to levels of osteoprotegerin and sensitivity to TRAIL-induced cell death in pancreatic ductal adenocarcinoma cells. Experimental and Molecular Pathology, 2013, 94, 372-379.	2.1	9
44	Structure-Based Peptide Mimicry of Tumor-Associated Antigens. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2013, 32, 1-5.	1.6	4
45	Probing Structural Variability at the N Terminus of the TSH Receptor with a Murine Monoclonal Antibody That Distinguishes between Two Receptor Conformational Forms. Endocrinology, 2013, 154, 562-571.	2.8	8
46	Mitochondrial protein BmPAPI modulates the length of mature piRNAs. Rna, 2013, 19, 1405-1418.	3.5	75
47	Mitochondrial NDUFS3 regulates the ROS-mediated onset of metabolic switch in transformed cells. Biology Open, 2013, 2, 295-305.	1.2	35
48	Structure Based Antibody-Like Peptidomimetics. Pharmaceuticals, 2012, 5, 209-235.	3.8	21
49	The promise of the anti-idiotype concept. Frontiers in Oncology, 2012, 2, 196.	2.8	28
50	Structure of Sad1-UNC84 Homology (SUN) Domain Defines Features of Molecular Bridge in Nuclear Envelope. Journal of Biological Chemistry, 2012, 287, 5317-5326.	3.4	114
51	Disabling the mitotic spindle and tumor growth by targeting a cavity-induced allosteric site of survivin. Oncogene, 2012, 31, 1938-1948.	5.9	37
52	A structural modulator of tumor necrosis factor type 1 receptor promotes bone formation under lipopolysaccharide-induced inflammation in a murine tooth extraction model. European Journal of Pharmacology, 2012, 679, 132-138.	3.5	8
53	Carbohydrate Mimetic Peptide Vaccines. , 2012, , 229-254.		0
54	Development of anti-EGF receptor peptidomimetics (AERP) as tumor imaging agent. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2550-2553.	2.2	7

#	Article	IF	CITATIONS
55	SSTR2-Based Reporters for Assessing Gene Transfer into Non–Small Cell Lung Cancer: Evaluation Using an Intrathoracic Mouse Model. Human Gene Therapy, 2011, 22, 55-64.	2.7	26
56	Anti-HER2/Neu Peptide Mimetic. , 2011, , 210-213.		0
57	Cloning and characterization of rhesus IL-18 binding protein, a natural antagonist to IL-18. Cytokine, 2010, 51, 232-239.	3.2	6
58	Targeting erbB receptors. Seminars in Cell and Developmental Biology, 2010, 21, 961-966.	5.0	26
59	Structure and conformation of linear peptides. IX. Structure of l-tyrosyl-l-phenylalanine. International Journal of Peptide and Protein Research, 2009, 29, 187-192.	0.1	8
60	Fn14-TRAIL, a Chimeric Intercellular Signal Exchanger, Attenuates Experimental Autoimmune Encephalomyelitis. American Journal of Pathology, 2009, 174, 460-474.	3.8	28
61	A comprehensive analysis of the naturally occurring polymorphisms in HIV-1 Vpr: Potential impact on CTL epitopes. Virology Journal, 2008, 5, 99.	3.4	10
62	Polymersomes: A new multi-functional tool for cancer diagnosis and therapy. Methods, 2008, 46, 25-32.	3.8	191
63	Structural basis for ligand-mediated mouse GITR activation. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 641-645.	7.1	45
64	Human glucocorticoid-induced TNF receptor ligand regulates its signaling activity through multiple oligomerization states. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5465-5470.	7.1	45
65	An Osteoprotegerin-like Peptidomimetic Inhibits Osteoclastic Bone Resorption and Osteolytic Bone Disease in Myeloma. Cancer Research, 2007, 67, 202-208.	0.9	80
66	Preclinical studies of carbohydrate mimetic peptide vaccines for breast cancer and melanoma. Vaccine, 2007, 25, 3022-3031.	3.8	36
67	ErbB receptors: from oncogenes to targeted cancer therapies. Journal of Clinical Investigation, 2007, 117, 2051-2058.	8.2	478
68	AHNP-streptavidin: a tetrameric bacterially produced antibody surrogate fusion protein against p185her2/neu. Oncogene, 2006, 25, 7740-7746.	5.9	26
69	A TNF receptor loop peptide mimic blocks RANK ligand–induced signaling, bone resorption, and bone loss. Journal of Clinical Investigation, 2006, 116, 1525-1534.	8.2	122
70	Disabling TNF receptor signaling by induced conformational perturbation of tryptophan-107. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 10970-10975.	7.1	35
71	HER2-Mediated Internalization of a Targeted Prodrug Cytotoxic Conjugate Is Dependent on the Valency of the Targeting Ligand. DNA and Cell Biology, 2005, 24, 351-358.	1.9	28
72	Disabling of Receptor Activator of Nuclear Factor-κB (RANK) Receptor Complex by Novel Osteoprotegerin-like Peptidomimetics Restores Bone Loss in Vivo. Journal of Biological Chemistry, 2004, 279, 8269-8277.	3.4	83

#	Article	IF	CITATIONS
73	Fas-disabling small exocyclic peptide mimetics limit apoptosis by an unexpected mechanism. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 6599-6604.	7.1	30
74	HIV-1 Vpr: Genetic Diversity and Functional Features from the Perspective of Structure. DNA and Cell Biology, 2004, 23, 207-222.	1.9	14
75	The Centrosome in Normal and Transformed Cells. DNA and Cell Biology, 2004, 23, 475-489.	1.9	51
76	The TNF Receptor Superfamily: Role in Immune Inflammation and Bone Formation. Immunologic Research, 2003, 27, 287-294.	2.9	29
77	Structure-Based Approaches to Inhibition of erbB Receptors with Peptide Mimetics. Immunologic Research, 2003, 27, 303-308.	2.9	4
78	Antibody like peptidomimetics as large scale immunodetection probes. Cellular and Molecular Biology, 2003, 49, 209-16.	0.9	3
79	Characterization of Mouse tGolgin-1 (Golgin-245/trans-Golgi p230/256 kD Golgin) and Its Upregulation during Oligodendrocyte Development. DNA and Cell Biology, 2002, 21, 505-517.	1.9	6
80	Disabling Receptor Ensembles with Rationally Designed Interface Peptidomimetics. Journal of Biological Chemistry, 2002, 277, 28330-28339.	3.4	82
81	TNFα Inhibition in MRL/lpr Mice Ameliorates Pulmonary but not Renal Disease. Journal of Autoimmunity, 2002, 19, 215-222.	6.5	12
82	Deoxycholate-Based Method to Screen Phage Display Clones for Uninterrupted Open Reading Frames. BioTechniques, 2002, 33, 294-296.	1.8	3
83	Study of Disabling T-Cell Activation and Inhibiting T-Cell-Mediated Immunopathology Reveals a Possible Inverse Agonist Activity of CD4 Peptidomimetics. Experimental and Molecular Pathology, 2002, 73, 93-103.	2.1	5
84	Disabling ErbB Receptors with Rationally Designed Exocyclic Mimetics of Antibodies:Â Structureâ^'Function Analysisâ€. Journal of Medicinal Chemistry, 2001, 44, 2565-2574.	6.4	99
85	The hidden code in genomics: a tool for gene discovery. Journal of Molecular Recognition, 2001, 14, 269-272.	2.1	7
86	Evolutionarily divergent electron donor proteins interact with P450MT2 through the same helical domain but different contact points. EMBO Journal, 2001, 20, 2394-2403.	7.8	19
87	Modifying TNF alpha for Therapeutic Use A Perspective on the TNF Receptor System. Mini-Reviews in Medicinal Chemistry, 2001, 1, 5-16.	2.4	27
88	Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nature Biotechnology, 2000, 18, 194-198.	17.5	175
89	HER2/Neu: mechanisms of dimerization/oligomerization. Oncogene, 2000, 19, 6093-6101.	5.9	144
90	Epitope-Tagging Approach to Determine the Stoichiometry of the Structural and Nonstructural Proteins in the Virus Particles: Amount of Vpr in Relation to Gag in HIV-1. Virology, 2000, 268, 364-371.	2.4	24

#	Article	IF	CITATIONS
91	Functional Role of Residues Corresponding to Helical Domain II (Amino Acids 35 to 46) of Human Immunodeficiency Virus Type 1 Vpr. Journal of Virology, 2000, 74, 10650-10657.	3.4	37
92	Extent of incorporation of HIV-1 Vpr into the virus particles is flexible and can be modulated by expression level in cells. FEBS Letters, 2000, 469, 191-195.	2.8	9
93	Design And Development Of Small-molecule Inhibitor Of Tumor Necrosis Factor , 2000, , .		0
94	New perspectives on anti-HER2/neu therapeutics. Drug News and Perspectives, 2000, 13, 325-9.	1.5	5
95	Structure of Taq DNA polymerase shows a new orientation for the structure-specific nuclease domain. Acta Crystallographica Section D: Biological Crystallography, 1999, 55, 1971-1977.	2.5	11
96	Shared Antigenic Epitopes and Pathobiological Functions of Anti-p185her2/neu Monoclonal Antibodies. Experimental and Molecular Pathology, 1999, 67, 15-25.	2.1	42
97	The Synthetic CD4 Exocyclic CDR3.AME(82-89) Inhibits NF-kappaB Nuclear Translocation, HIV-1 Promoter Activation, and Viral Gene Expression. DNA and Cell Biology, 1999, 18, 819-828.	1.9	3
98	Structure based design and characterization of exocyclic peptidomimetics that inhibit TNF1 \pm binding to its receptor. , 1999, , 61-63.		0
99	Structure of Taq DNA polymerase shows a new orientation for the structure-specific nuclease domain. Acta Crystallographica Section D: Biological Crystallography, 1999, 55, 1971-1977.	2.5	10
100	Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: implications for subdomain contributions to receptor assembly. Oncogene, 1998, 16, 1197-1207.	5.9	52
101	Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential. Oncogene, 1998, 16, 2835-2842.	5.9	24
102	Structure-based design of immunologically active therapeutic peptides. Immunologic Research, 1998, 17, 163-169.	2.9	24
103	Structural Studies of Synthetic Peptide Fragments Derived from the HIV-1 Vpr Protein. Biochemical and Biophysical Research Communications, 1998, 244, 732-736.	2.1	26
104	Crystal structure of Taq DNA polymerase in complex with an inhibitory Fab: The Fab is directed against an intermediate in the helix-coil dynamics of the enzyme. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 12562-12567.	7.1	28
105	Structural studies on an inhibitory antibody against Thermus aquaticus DNA polymerase suggest mode of inhibition. Protein Engineering, Design and Selection, 1998, 11, 79-86.	2.1	11
106	Transduction of Activation Signal That Follows HIV-1 Binding to CD4 and CD4 Dimerization Involves the Immunoglobulin CDR3-like Region in Domain 1 of CD4. Journal of Biological Chemistry, 1997, 272, 19441-19450.	3.4	39
107	The Crystal Structure of a Fab Fragment to the Melanoma-Associated GD2 Ganglioside. Journal of Structural Biology, 1997, 119, 6-16.	2.8	40
108	Therapeutic peptides and peptidomimetics. Current Opinion in Biotechnology, 1997, 8, 435-441.	6.6	82

#	Article	IF	CITATIONS
109	Structure–based design and characterization of exocyclic peptidomimetics that inhibit TNFα binding to its receptor. Nature Biotechnology, 1997, 15, 1266-1270.	17.5	118
110	Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes. Nature Biotechnology, 1997, 15, 150-154.	17.5	44
111	Molecular recognition of a peptide mimic of the Lewis Y antigen by an anti-Lewis Y antibody. Journal of Molecular Recognition, 1997, 10, 269-276.	2.1	22
112	Effect of Mutagenesis of GPIIb Amino Acid 273 on the Expression and Conformation of the Platelet Integrin GPIIb-Illaâ€. Biochemistry, 1996, 35, 14304-14311.	2.5	22
113	Molecular Structure, Conformational Analysis, and Structureâ [~] 'Activity Studies of Dendrotoxin and Its Homologues Using Molecular Mechanics and Molecular Dynamics Techniques. Journal of Medicinal Chemistry, 1996, 39, 2141-2155.	6.4	18
114	Structural analysis of p185c-neu and epidermal growth factor receptor tyrosine kinases: oligomerization of kinase domains Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 6252-6257.	7.1	43
115	Synthetic CD4 exocyclic peptides antagonize CD4 holoreceptor binding and T cell activation. Nature Biotechnology, 1996, 14, 472-475.	17.5	42
116	Arginine at positions 13 or 70-71 in pocket 4 of HLA-DRB1 alleles is associated with susceptibility to tuberculoid leprosy Journal of Experimental Medicine, 1996, 183, 829-836.	8.5	99
117	Molecular recognition of the Lewis Y antigen by monoclonal antibodies. Protein Engineering, Design and Selection, 1996, 9, 447-459.	2.1	27
118	Preliminary crystallographic data for an Fab to the melanoma-associated GD2 ganglioside, and the purification of a soluble form of this antigen. Acta Crystallographica Section D: Biological Crystallography, 1995, 51, 124-126.	2.5	2
119	Mutagenesis of the putative alpha-helical domain of the Vpr protein of human immunodeficiency virus type 1: effect on stability and virion incorporation Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 3794-3798.	7.1	76
120	Crystallization and Preliminary X-ray Analysis of Human α-Galactosidase A Complex. Journal of Molecular Biology, 1994, 239, 578-580.	4.2	25
121	The Refined Crystal Structure of Hexon, the Major Coat Protein of Adenovirus Type 2, at 2·9 Ã Resolution. Journal of Molecular Biology, 1994, 242, 430-455.	4.2	133
122	Role of tryptophan repeats and flanking amino acids in Myb-DNA interactions Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 8452-8456.	7.1	135
123	Structure and conformation of linear peptides. X. Structure of glycylâ€glycylâ€Lâ€phenylalanine hydrochloride. International Journal of Peptide and Protein Research, 1987, 29, 374-380.	0.1	5
124	Structure and conformation of linear peptides. International Journal of Peptide and Protein Research, 1986, 27, 478-482.	0.1	5